Amplex AB publishes supplement to the offer document regarding the cash offer to the shareholders and warrantholders of ADDvise Group AB (publ)

Amplex AB has revised its cash offer for ADDvise Group AB, raising the bid from SEK 1.65 to SEK 1.72 per A- and B-share and from SEK 0.49 to SEK 0.52 per warrant (TO1A/TO1B). Amplex has entered conditional acquisition agreements with five major shareholders who together control ~21.11% of share capital (~16.55% of votes), and with prior commitments and holdings now controls approximately 51.49% of capital and 60.57% of votes, materially improving the probability of a successful takeover. The transaction is governed by Swedish takeover rules and contains extensive distribution and jurisdictional restrictions; if completed, the deal would likely consolidate control and could lead to squeeze-out/delisting outcomes for minority holders.

Analysis

Market structure: This is a classic small‑cap takeover arbitrage where Amplex has raised its cash bid to SEK 1.72 and assembled ~51.5% of capital / ~60.6% of votes — materially increasing probability of deal completion. Winners are existing selling shareholders and Amplex (control); losers are passive minority holders who may be squeezed out at the offered price if no competing bidder emerges. The pragmatic effect is concentration of ownership in ADDvise and likely de‑listing / illiquidity for the stock post‑close within 1–3 months.

Risk assessment: Primary tail risks are a competing bid (>+10–20% above SEK 1.72), regulatory blocks, or Amplex financing failure; assign baseline deal‑close probability ~70–85% given >50% capital locked but reduce to ~50% if aggregate commitments are conditional. Immediate (days) volatility will be driven by news of acceptances/financing; short‑term (weeks) by competing bids; long‑term (quarters) by integration outcomes and any squeeze‑out litigation. Hidden dependency: off‑market acquisitions by Amplex or advisors may shift the market price unpredictably.

Trade implications: Direct play is arbitrage in ADDvise (buy target vs cash takeover price), sizing small (2–4% NAV) because liquidity is thin; use short‑dated call spreads if options exist to cap capital at known risk. Relative value: pair long ADDvise / short a Swedish small‑cap life‑science basket to neutralize sector beta. Cross‑asset: minimal FX or commodity impact; small tightening in credit of buyers if financed by debt could widen AA‑/BBB spreads marginally.

Contrarian angle: Consensus may underprice squeeze‑out certainty — with >60% votes Amplex can likely force minority exit, so upside beyond SEK 1.72 is limited absent a rival bidder; the mispricing is on deal timing risk rather than deal economics. If you believe financing is weak, short Amplex equity (or buy CDS if listed) on a financing announcement; conversely avoid paying up for speculative takeover premium above 5% unless clear competing bid signals appear.

Key Decisions for Investors

• Establish a 2–3% NAV long position in ADDvise AB shares if market price <= SEK 1.68 (spread ≥2.4%), target capture to SEK 1.72 within 30–90 days; trim to zero if a competing bid appears above SEK 1.90 or if Amplex announces financing difficulties.
• If liquid options exist, buy 3‑month ATM call spreads on ADDvise (buy ATM, sell +6–8% strike) sized to cap max premium to 0.5–1.0% NAV — this expresses deal close view with defined downside and funds part of premium with sold calls.
• Establish a 1–2% NAV pair trade: long ADDvise vs short a Swedish small‑cap life‑science basket (or ETF) to neutralize sector beta; close both if offer extended beyond 120 days or competing bid >+10% emerges.
• If Amplex is publicly traded, selectively short 0.5–1.0% NAV of Amplex on any announced debt financing or equity raise (hold 30–120 days); cover if deal financing is equity‑light (cash on hand ≥ announced purchase price) or if Arbitral rulings favor acceptance.